Clinical Trial Detail

NCT ID NCT04117945
Title Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Academic and Community Cancer Research United
Indications

colorectal adenocarcinoma

Therapies

Regorafenib

Irinotecan + Panitumumab

Panitumumab

Cetuximab + Irinotecan

Cetuximab

Age Groups: adult senior

Additional content available in CKB BOOST